Given retail took up hardly any of the raise there
may not be much selling as the share price
recovers. This is an interesting play given Doctors
will be administering the bulk of the tests in the
CLIA Waiver trial which will take about 12
months from trial beginning to FDA decision time.
Was thinking today this might result in a gradual
run up the way BOT did into FDA approval.
Preserving the effectiveness of antibiotics is going
to be a strong theme going forward hence
BARDA’S involvement I’m sure.
Ann: Change in substantial holding from RYD, page-15
Add to My Watchlist
What is My Watchlist?
